SCLERODERMA AB IGG

Code
900.3910
Name
SCLERODERMA AB IGG
Category
None
Department
Send-Out
Start Date
Expiration Date
Synonyms
Scl-70; ENA; Extractable Nuclear Antigen
CPT Codes
86235
Site
SBMF
Reference Test
28335
ATLAS Test Code

Specimen Information

Type

Gold, SST

Volume

1.0 ml

Transport Info

Refrigerated

Fasting Required?
False
Patient Instructions

Reference Range

See Report

Methodology

Multiplex Flow Immunoassay

Clinical Significance

The term "anti-nuclear antibodies" describes a variety of autoantibodies that react with constituents of cell nuclei, including DNA, RNA, and several proteins and ribonucleoproteins. These autoantibodies occur with high frequency in patients with connective tissue or rheumatic diseases, especially systemic lupus erythematosus (SLE). The current trend in diagnosing and managing connective tissue disease is to combine a sensitive ANA screening test with more specific follow-up tests such as antibody to double stranded DNA (dsDNA) and extractable nuclear antigens (ENA). The newer ENA tests are becoming especially important as they provide both diagnostic and prognostic information. When Scl-70 is the only autoantibody present, it is a specific marker for scleroderma. Similar specificity is seen with other autoantibodies; for example, antibodies to Smith antigen (Sm) and native DNA are specific marker autoantibodies for SLE. Scl-70 antibodies are considered highly diagnostic and specific for scleroderma (20-60% positive) and are seen in 25% of progressive systemic sclerosis (PSS). The wide range in the reported frequency of Scl-70 antibody may be due to differences in assay sensitivity. When scleroderma patients are divided into those with the milder CREST Syndrome variant and the more severe diffuse form (PSS), Scl-70 antibodies are found to be more prevalent in diffuse scleroderma patients (greater than 70%) compared to the milder disease group. Multiple autoantibodies may indicate MCTD or other autoimmune diseases.

Back